Agenus Inc (NASDAQ:AGEN) shares were down 5.6% during trading on Thursday . The company traded as low as $1.95 and last traded at $2.02. Approximately 1,233,377 shares traded hands during mid-day trading, a decline of 20% from the average daily volume of 1,547,618 shares. The stock had previously closed at $2.14.
A number of research analysts have recently commented on AGEN shares. Zacks Investment Research cut shares of Agenus from a “hold” rating to a “sell” rating in a report on Monday, July 23rd. BidaskClub cut shares of Agenus from a “strong-buy” rating to a “buy” rating in a report on Monday, June 18th.
The company has a current ratio of 1.32, a quick ratio of 1.32 and a debt-to-equity ratio of -0.11. The firm has a market capitalization of $250.35 million, a P/E ratio of -1.73 and a beta of 1.70.
Agenus (NASDAQ:AGEN) last posted its quarterly earnings results on Thursday, August 9th. The biotechnology company reported ($0.24) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.40) by $0.16. equities analysts forecast that Agenus Inc will post -1.2 EPS for the current fiscal year.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Jane Street Group LLC bought a new position in shares of Agenus in the second quarter worth about $101,000. RTW Investments LP grew its holdings in Agenus by 0.7% during the 2nd quarter. RTW Investments LP now owns 9,375,451 shares of the biotechnology company’s stock worth $21,282,000 after acquiring an additional 61,895 shares in the last quarter. BlackRock Inc. grew its holdings in Agenus by 15.7% during the 2nd quarter. BlackRock Inc. now owns 5,717,966 shares of the biotechnology company’s stock worth $12,980,000 after acquiring an additional 776,715 shares in the last quarter. Schwab Charles Investment Management Inc. grew its holdings in Agenus by 9.8% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 383,085 shares of the biotechnology company’s stock worth $870,000 after acquiring an additional 34,065 shares in the last quarter. Finally, Allianz Asset Management GmbH grew its holdings in Agenus by 6.3% during the 1st quarter. Allianz Asset Management GmbH now owns 245,965 shares of the biotechnology company’s stock worth $1,158,000 after acquiring an additional 14,634 shares in the last quarter. Hedge funds and other institutional investors own 35.34% of the company’s stock.
About Agenus (NASDAQ:AGEN)
Agenus Inc, a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies.
Read More: Calculate Your Return on Investment (ROI)
Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.